LAVA Therapeutics (NASDAQ:LVTX) Issues Quarterly Earnings Results

LAVA Therapeutics (NASDAQ:LVTX) released its earnings results on Friday. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.18, Zacks reports. The company had revenue of $2.50 million during the quarter, compared to the consensus estimate of $2.40 million.

LAVA Therapeutics Price Performance

Shares of NASDAQ LVTX traded down $0.01 during mid-day trading on Friday, hitting $1.29. The company had a trading volume of 43,333 shares, compared to its average volume of 173,459. The stock has a market cap of $33.92 million, a price-to-earnings ratio of -1.25 and a beta of 0.48. The firm’s 50 day simple moving average is $1.13 and its two-hundred day simple moving average is $1.37. LAVA Therapeutics has a 12 month low of $0.85 and a 12 month high of $3.57.

Wall Street Analyst Weigh In

LVTX has been the subject of a number of research reports. Leerink Partners reiterated a “market perform” rating and issued a $2.00 price target (down from $11.00) on shares of LAVA Therapeutics in a research note on Thursday, December 12th. Leerink Partnrs lowered LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. JMP Securities restated a “market perform” rating and set a $6.00 price objective on shares of LAVA Therapeutics in a research note on Wednesday, December 11th. Citizens Jmp downgraded shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 11th. Finally, HC Wainwright reissued a “neutral” rating and set a $1.50 target price (down from $2.00) on shares of LAVA Therapeutics in a report on Thursday, February 27th. Five investment analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $3.17.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.